{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:07:25Z","timestamp":1793117245218,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100013944","name":"Institut de Canc\u00e9rologie de Lorraine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013944","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.radonc.2018.08.008","type":"journal-article","created":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T14:17:38Z","timestamp":1535552258000},"page":"463-470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Prognostic factors of colostomy free survival in patients presenting with locally advanced anal canal carcinoma: A pooled analysis of two prospective trials (KANAL 2 and ACCORD 03)"],"prefix":"10.1016","volume":"129","author":[{"given":"Jean-Christophe","family":"Faivre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Peiffert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Vendrely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Lemanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Hannoun-Levi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Mirabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Stanbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Salleron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Guillemin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2018.08.008_b0005","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdu159","article-title":"Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Glynne-Jones","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2018.08.008_b0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ctrv.2018.02.001","article-title":"Anal squamous cell carcinoma \u2013 State of the art management and future perspectives","volume":"65","author":"Martin","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.radonc.2018.08.008_b0015","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1200\/JCO.2012.44.2293","article-title":"Capturing data on colostomy formation in anal cancer","volume":"31","author":"Glynne-Jones","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2018.08.008_b0020","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/S1470-2045(17)30587-9","article-title":"Nodal status and survival in anal cancer","volume":"18","author":"Perez","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2018.08.008_b0025","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"Bartelink","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2018.08.008_b0030","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","article-title":"Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial","volume":"299","author":"Ajani","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.radonc.2018.08.008_b0035","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/annonc\/mdu188","article-title":"Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial","volume":"25","author":"Glynne-Jones","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2018.08.008_b0040","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.radonc.2017.06.009","article-title":"External validation of leukocytosis and neutrophilia as a prognostic marker in anal carcinoma treated with definitive chemoradiation","volume":"124","author":"Schernberg","year":"2017","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.radonc.2018.08.008_b0045","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.radonc.2016.12.009","article-title":"Leukocytosis and neutrophilia predicts outcome in anal cancer","volume":"122","author":"Schernberg","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2018.08.008_b0050","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/annonc\/mdx029","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal","volume":"28","author":"Ott","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2018.08.008_b0055","article-title":"Stereotactic body radiotherapy with helical tomotherapy for pain palliation in spine metastasis","author":"Kim","year":"2013","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.radonc.2018.08.008_b0060","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1093\/annonc\/mdt368","article-title":"Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial","volume":"24","author":"Deutsch","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2018.08.008_b0065","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/COC.0000000000000009","article-title":"Intensity-modulated radiation therapy for anal cancer: results from a multi-institutional retrospective cohort study","volume":"39","author":"Call","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.radonc.2018.08.008_b0070","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.adro.2017.01.009","article-title":"Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529","volume":"2","author":"Mitra","year":"2017","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.radonc.2018.08.008_b0075","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20150832","article-title":"Volumetric modulated arc therapy (VMAT) in the combined modality treatment of anal cancer patients","author":"Franco","year":"2016","journal-title":"Br J Radiol"},{"key":"10.1016\/j.radonc.2018.08.008_b0080","first-page":"2027","article-title":"Locally advanced (T3\u2013T4 or N+) anal cancer treated with simultaneous integrated boost radiotherapy and concurrent chemotherapy","volume":"36","author":"Franco","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1016\/j.radonc.2018.08.008_b0085","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3109\/0284186X.2015.1124141","article-title":"Clinical outcome in patients treated with simultaneous integrated boost - intensity modulated radiation therapy (SIB-IMRT) with and without concurrent chemotherapy for squamous cell carcinoma of the anal canal","volume":"55","author":"Tomasoa","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2018.08.008_b0090","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.radonc.2016.06.020","article-title":"Patient reported quality of life after helical IMRT based concurrent chemoradiation of locally advanced anal cancer","volume":"120","author":"Joseph","year":"2016","journal-title":"Radiother Oncol J"},{"key":"10.1016\/j.radonc.2018.08.008_b0095","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.radonc.2015.09.009","article-title":"Modeling early haematologic adverse events in conformal and intensity-modulated pelvic radiotherapy in anal cancer","volume":"117","author":"Robinson","year":"2015","journal-title":"Radiother Oncol J"},{"key":"10.1016\/j.radonc.2018.08.008_b0100","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1023\/A:1011107105538","article-title":"High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: final results of a phase II study","volume":"12","author":"Peiffert","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2018.08.008_b0105","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","article-title":"Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial","volume":"30","author":"Peiffert","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2018.08.008_b0110","series-title":"Modeling survival data: extending the cox model","author":"Therneau","year":"2000"},{"key":"10.1016\/j.radonc.2018.08.008_b0115","doi-asserted-by":"crossref","unstructured":"Therneau TM. Extending the Cox Model; 1996","DOI":"10.1007\/978-1-4684-6316-3_5"},{"key":"10.1016\/j.radonc.2018.08.008_b0120","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1002\/sim.4780111607","article-title":"A bootstrap resampling procedure for model building: application to the Cox regression model","volume":"11","author":"Sauerbrei","year":"1992","journal-title":"Stat Med"},{"key":"10.1016\/j.radonc.2018.08.008_b0125","series-title":"Clinical prediction models: a practical approach to development, validation, and updating","author":"Steyerberg","year":"2009"},{"key":"10.1016\/j.radonc.2018.08.008_b0130","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.radonc.2018.08.008_b0135","doi-asserted-by":"crossref","unstructured":"Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet; 1996; 348: 1049\u201354.","DOI":"10.1016\/S0140-6736(96)03409-5"},{"key":"10.1016\/j.radonc.2018.08.008_b0140","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/sj.bjc.6605605","article-title":"Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I)","volume":"102","author":"Northover","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2018.08.008_b0145","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","article-title":"Long-term update of US GI intergroup RTOG 98\u201311 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin","volume":"30","author":"Gunderson","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2018.08.008_b0150","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 \u00d7 2 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2018.08.008_b0155","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1002\/cncr.25188","article-title":"Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98\u201311)","volume":"116","author":"Ajani","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2018.08.008_b0160","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.ijrobp.2005.05.047","article-title":"Prognostic value of tumor regression evaluated after first course of radiotherapy for anal canal cancer","volume":"63","author":"Chapet","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2018.08.008_b0165","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ijrobp.2010.01.010","article-title":"High-grade acute organ toxicity as a positive prognostic factor in primary radiochemotherapy for anal carcinoma","volume":"79","author":"Wolff","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2018.08.008_b0170","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1470-2045(13)70121-9","article-title":"ACT II: treatment of anal cancer comes full circle","volume":"14","author":"Willett","year":"2013","journal-title":"Lancet Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814018334467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814018334467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:08:18Z","timestamp":1759122498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814018334467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0167814018334467"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2018.08.008","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic factors of colostomy free survival in patients presenting with locally advanced anal canal carcinoma: A pooled analysis of two prospective trials (KANAL 2 and ACCORD 03)","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2018.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}